ArticleOncogene2004
Gene expression profiling and subgroup identification of oligodendrogliomas.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 56 citations in OpenAlex.
- MicroRNA-10b-5p downregulation inhibits the invasion of glioma cells via modulating homeobox B3 expression.Experimental and therapeutic medicine · 2019Article
- The long non-coding RNA LOC441204 enhances cell growth in human glioma.Scientific reports · 2017Article
- Pediatric low-grade gliomas: how modern biology reshapes the clinical field.Biochimica et biophysica acta · 2014Review
- Long noncoding RNA profiles reveal three molecular subtypes in glioma.CNS neuroscience & therapeutics · 2014Article
- To BRAF or not to BRAF: is that even a question anymore?Journal of neuropathology and experimental neurology · 2013Review
- Something old and something new about molecular diagnostics in gliomas.Surgical pathology clinics · 2012Article
- Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.Neuro-oncology · 2012Article
- Biology, genetics and imaging of glial cell tumours.The British journal of radiology · 2011Review
- EGFR expression stratifies oligodendroglioma behavior.The American journal of pathology · 2011Article
- Gene expression in oligodendroglial tumors.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- Tumor profiling: development of prognostic and predictive factors to guide brain tumor treatment.Current oncology reports · 2011Review
- The use of global profiling in biomarker development for gliomas.Brain pathology (Zurich, Switzerland) · 2011Review
- KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells.Brain pathology (Zurich, Switzerland) · 2010Article
- Review
- Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.Neuro-oncology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The histological diagnosis of low-grade astrocytomas and oligodendrogliomas (WHO grade II) is often challenging, particularly in cases that show both astrocytic and oligodendroglial differentiation. We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q) and 15 low-grade astrocytomas (71% with a TP53 mutation), using a cDNA array containing 1176 cancer-related genes. In oligodendrogliomas, 40 genes showed on average higher expression (at least a two-fold increase) than in astrocytomas, including DES, TDGF1, TGF-beta, GABA-BR1A, Histone H4, CDKN1A, PCDH43, Rho7 and Jun-D, while 39 genes were expressed at lower levels (at least a two-fold decrease), including JNK2, ITGB4, JNK3A2, RhoC, IFI-56K, AAD14 and EGFR. Immunohistochemistry revealed nuclear staining of Jun-D in oligodendrogliomas, in contrast to the immunoreactivity of cytoplasm and cell processes in low-grade astrocytomas. Partial least-squares analysis of the 79 genes at least two-fold differentially expressed between oligodendrogliomas and low-grade astrocytomas demonstrated perfect separation of oligodendrogliomas from low-grade astrocytomas and normal cerebral white matter. Clustering analysis based on the entire gene set divided the 17 subjects with oligodendrogliomas into two subgroups with significantly different survival (log-rank test, P=0.0305; survival to 5-years, 80 vs 0%, P=0.048). These results demonstrate that oligodendrogliomas and low-grade astrocytomas differ in their gene expression profiles, and that there are subgroups of oligodendroglioma with distinct expression profiles related to clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.